Zacks Investment Research lowered shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) from a buy rating to a hold rating in a report issued on Tuesday morning.

According to Zacks, “Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. “

Other analysts have also issued reports about the company. Cowen and Company reissued a buy rating on shares of Corvus Pharmaceuticals in a report on Tuesday, June 6th. Credit Suisse Group raised Corvus Pharmaceuticals from an underperform rating to a neutral rating and set a $14.00 price objective for the company in a report on Wednesday, August 23rd. Finally, Wedbush reissued an outperform rating and set a $26.00 price objective on shares of Corvus Pharmaceuticals in a report on Tuesday, August 8th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Corvus Pharmaceuticals has a consensus rating of Buy and an average price target of $20.75.

Shares of Corvus Pharmaceuticals (NASDAQ CRVS) opened at 16.99 on Tuesday. The firm has a 50 day moving average price of $13.23 and a 200 day moving average price of $12.89. Corvus Pharmaceuticals has a one year low of $8.27 and a one year high of $22.14. The company’s market capitalization is $355.67 million.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its earnings results on Thursday, August 3rd. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.03. On average, equities research analysts predict that Corvus Pharmaceuticals will post ($3.18) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Corvus Pharmaceuticals, Inc. (CRVS) Cut to “Hold” at Zacks Investment Research” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/09/09/corvus-pharmaceuticals-inc-crvs-cut-to-hold-at-zacks-investment-research.html.

In other news, insider Richard A. Md Miller acquired 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 13th. The shares were acquired at an average price of $9.88 per share, for a total transaction of $247,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Holdings A/S Novo acquired 20,000 shares of the company’s stock in a transaction that occurred on Friday, June 23rd. The stock was purchased at an average price of $10.95 per share, for a total transaction of $219,000.00. Following the purchase, the insider now owns 3,244,046 shares of the company’s stock, valued at approximately $35,522,303.70. The disclosure for this purchase can be found here.

A number of institutional investors have recently bought and sold shares of CRVS. EcoR1 Capital LLC purchased a new position in Corvus Pharmaceuticals in the second quarter valued at approximately $9,741,000. Jennison Associates LLC lifted its stake in Corvus Pharmaceuticals by 87.4% in the second quarter. Jennison Associates LLC now owns 1,019,013 shares of the company’s stock valued at $12,330,000 after purchasing an additional 475,164 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Corvus Pharmaceuticals in the first quarter valued at approximately $8,480,000. JPMorgan Chase & Co. lifted its stake in Corvus Pharmaceuticals by 116.0% in the second quarter. JPMorgan Chase & Co. now owns 332,634 shares of the company’s stock valued at $4,025,000 after purchasing an additional 178,658 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Corvus Pharmaceuticals by 37.1% in the second quarter. Vanguard Group Inc. now owns 373,512 shares of the company’s stock valued at $4,520,000 after purchasing an additional 101,013 shares during the last quarter. Institutional investors and hedge funds own 83.63% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

Get a free copy of the Zacks research report on Corvus Pharmaceuticals (CRVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.